Pharmaceuticals

Intravenous Iron Drugs Industry Poised for Rapid Growth, Forecast to Touch $6.34 Billion by 2030 at 10.7% CAGR

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the intravenous iron drugs market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Intravenous Iron Drugs Market by the end of 2030?

The intravenous iron drugs market size has experienced rapid growth recently. It is set to expand from $3.81 billion in 2025 to $4.22 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This historical growth can be credited to the high prevalence of iron deficiency anemia, limitations associated with oral iron absorption, hospital-based anemia management protocols, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.

The market for intravenous iron drugs is anticipated to experience swift expansion over the coming years, reaching a valuation of $6.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This projected growth during the forecast timeframe stems from factors such as an escalating burden of chronic diseases, an expanding demographic of dialysis patients, a rise in anemia cases linked to cancer, a preference for quick hemoglobin restoration, and the broadening availability of outpatient infusion services. Key trends expected within this period encompass the increased application in managing iron deficiency anemia, greater uptake among individuals with chronic kidney disease, an escalating preference over traditional oral iron treatments, the proliferation of single-dose iron preparations, and enhanced usage across the fields of oncology and gastroenterology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Drivers Are Shaping Future Opportunities In The Intravenous Iron Drugs Market?

The increasing occurrence of chronic kidney disease (CKD) is anticipated to drive expansion in the intravenous iron drugs market moving ahead. CKD describes a progressive decline in kidney function where the kidneys gradually lose their capacity to efficiently remove waste products and surplus fluids from the bloodstream. This rise in CKD cases stems from the escalating prevalence of diabetes and hypertension, both of which contribute to long-term kidney damage. Intravenous iron medications assist CKD patients by restoring iron reserves, correcting anemia, and boosting hemoglobin concentrations, thereby improving oxygen delivery and decreasing reliance on erythropoiesis-stimulating agents. For example, data from July 2025 by Hamadan University of Medical Sciences, an Iran-based university, indicates a global projection of newly diagnosed chronic kidney diseases to reach 25.06 million by 2030. Consequently, the expanding incidence of chronic kidney disease (CKD) is fueling the development of the intravenous iron drugs market.

Which Segments Are Gaining Traction In The Intravenous Iron Drugs Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Guiding The Evolution Of The Intravenous Iron Drugs Market?

Leading companies in the intravenous iron drugs market are concentrating on developing novel treatments, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical intervention that delivers iron directly into the bloodstream through an intravenous infusion. This therapy addresses iron deficiency and anemia, especially for patients unable to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to improve exercise capacity. Injectafer is a widely used intravenous iron therapy recognized for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Primary Competitors In The Global Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Intravenous Iron Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795